| 16th June - 17h45 |
Targeted therapies in breast cancer: optimizing strategies for improvement outcomes
Chairman: E. P. Winer
Aromatase inhibitors in the adjuvant setting: impact of early distant metastases on Breast Cancer - C. Tondini
Bone health in Breast Cancer: emerging data and implications for treatment of early breast cancer - F. Bertoldo
Targeting mTOR pathway in Breast Cancer – G. Tortora
Supported by Novartis |
| 17th June - 10h30 |
Targeting cytotoxic treatments in advanced breast cancer patients by defining molecular profiles on circulating tumor cells
Chairman: E. Munzone
Speaker: A. Di Leo
Supported by Pierre Fabre Pharma |
| 17th June - 12h35 |
Lapatinib: current practice and future developments
Chairman: E. Munzone
Lapatinib: new information? - F. Montemurro
Cross Talk between EGFR family signalling pathways and estrogen receptors: a new therapeutic scenario? - F. Puglisi
Supported by GlaxoSmithKline |
| 17th June - 16h05 |
Exemestane: evidence and experience
Chairman: S. Cinieri
Speaker: V. Lorusso
Supported by Pfizer |
| 17th June - 18h10 |
HER2: a spectacular target
Chairman: A. Goldhirsch
Finding the target - G. Viale
Evolution of anti HER2 treatments - E. P. Winer
Supported by Roche |
| 18th June - 10h10 |
Efficacy and tolerability of fulvestrant 500mg - Results from CONFIRM
Chairman: S. Cinieri
Speaker: A. Di Leo
Supported by Astrazeneca |
| 18th June - 12h50 |
Angiogenesis: focus on patient-oriented therapies
Chairman: F. Bertolini
An overview on bevacizumab and cytotoxics - M. De Laurentiis
Antiangiogenesis and inflammatory presentation of Breast Cancer - G. Curigliano
Supported by Roche |
HOME PAGE
Wed, 16 june 2010